Role of albumin in diseases associated with severe systemic inflammation: Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis

• Published in: Journal of critical care 2016-06, Vol.33, p.62-70
• Main Authors: Artigas, Antonio, MD, Wernerman, Jan, MD, PhD, Arroyo, Vicente, MD, Vincent, Jean-Louis, MD, PhD, Levy, Mitchell, MD
• Format: Article
• Language: English
• Subjects: Albumin; Albumins - administration & dosage; Albumins - adverse effects; Albumins - metabolism; Albumins - therapeutic use; Blood Volume; Cirrhosis; Consortia; Critical Care; Failure; Fluids; Heart surgery; Hepatorenal syndrome; Hospitalization; Hospitals; Humans; Inflammation; Inflammation - complications; Inflammation - drug therapy; Liver Cirrhosis - complications; Liver Cirrhosis - drug therapy; Medicin och hälsovetenskap; Metabolism; Molecular weight; Mortality; Permeability; Physiology; Sepsis
• ISSN: 0883-9441; 1557-8615; 1557-8615
• DOI: 10.1016/j.jcrc.2015.12.019

Abstract The metabolism of albumin in inflammatory states such as sepsis or major surgery is complex and still not well characterized. Nevertheless, in inflammatory states, albumin synthesis has been observed to increase. By contrast, in decompensated cirrhosis, a disease characterized by systemic inflammation, albumin synthesis by the liver may decrease to 30% to 50% of normal values. Furthermore, in these conditions, there are high capillary leakage and altered albumin kinetics. The discussion regarding the effect of exogenous albumin administration on intravascular volume in inflammatory states should therefore address albumin turnover. To add complexity to our understanding of the effects of albumin, there are many data indicating that the therapeutic action of albumin is mediated not only through the impact on plasma volume expansion but also through a modulatory effect on inflammation and oxidative stress. All these characteristics are relevant to diseases associated with systemic inflammation including sepsis and decompensated cirrhosis.